Cellular source of soluble interleukin 2 receptors in serum of mice after recombinant interleukin 2 administration.

[1]  H. Young,et al.  Interleukin 2-induced proliferation of murine natural killer cells in vivo , 1990, The Journal of experimental medicine.

[2]  S. Dubinett,et al.  TUMOUR-INFILTRATING LYMPHOCYTES AND INTERLEUKIN-2 IN TREATMENT OF ADVANCED CANCER , 1989, The Lancet.

[3]  T. J. Hayes,et al.  Toxicity of human recombinant interleukin-2 in the mouse is mediated by interleukin-activated lymphocytes. Separation of efficacy and toxicity by selective lymphocyte subset depletion. , 1988, Laboratory investigation; a journal of technical methods and pathology.

[4]  T. J. Hayes,et al.  Role of asialo-GM1-positive lymphoid cells in mediating the toxic effects of recombinant IL-2 in mice. , 1988, Journal of immunology.

[5]  W. Greene,et al.  Novel interleukin 2 (IL-2) receptor appears to mediate IL-2-induced activation of natural killer cells. , 1988, The Journal of clinical investigation.

[6]  W. Leonard,et al.  The IL-2 receptor beta chain (p70): role in mediating signals for LAK, NK, and proliferative activities. , 1987, Science.

[7]  T. Malek,et al.  The murine interleukin 2 receptor. Irreversible cross-linking of radiolabeled interleukin 2 to high affinity interleukin 2 receptors reveals a noncovalently associated subunit. , 1987, Journal of immunology.

[8]  S. Rosenberg,et al.  Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2. , 1987, Journal of immunology.

[9]  B. Cullen,et al.  A second human interleukin-2 binding protein that may be a component of high-affinity interleukin-2 receptors , 1987, Nature.

[10]  T. Waldmann,et al.  Expression of functional IL 2 receptors by lipopolysaccharide and interferon-gamma stimulated human monocytes. , 1987, Journal of immunology.

[11]  S. Rosenberg,et al.  In vivo administration of purified human interleukin-2 to patients with cancer: development of interleukin-2 receptor positive cells and circulating soluble interleukin-2 receptors following interleukin-2 administration. , 1987, Cancer research.

[12]  C. Biron,et al.  Aberrant T cells in beige mutant mice. , 1987, Journal of immunology.

[13]  S. Hinuma,et al.  Suppression of pulmonary tumour metastasis in mice by recombinant human interleukin-2: role of asialo GM1-positive cells. , 1987, Immunology.

[14]  T. Waldmann,et al.  Demonstration of a non-Tac peptide that binds interleukin 2: a potential participant in a multichain interleukin 2 receptor complex. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[15]  S. Rosenberg,et al.  Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. , 1986, Journal of immunology.

[16]  J. Berzofsky,et al.  Antigen-specific murine T cell clones produce soluble interleukin 2 receptor on stimulation with specific antigens. , 1986, Journal of immunology.

[17]  J. Yodoi,et al.  Effect of interleukin 1 on the expression of interleukin 2 receptor (Tac antigen) on human natural killer cells and natural killer-like cell line (YT cells). , 1986, Journal of immunology.

[18]  J. Lowenthal,et al.  High and low affinity IL 2 receptors: analysis by IL 2 dissociation rate and reactivity with monoclonal anti-receptor antibody PC61. , 1985, Journal of immunology.

[19]  D. Nelson,et al.  Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro. , 1985, Journal of immunology.

[20]  J. Thompson,et al.  Interleukin 2 (IL 2) administered in vivo: influence of IL 2 route and timing on T cell growth. , 1985, Journal of immunology.

[21]  Craig W. Reynolds,et al.  Direct evidence for the role of LGL in the inhibition of experimental tumor metastases. , 1985, Journal of immunology.

[22]  J. Talmadge.  Immunoregulation and immunostimulation of murine lymphocytes by recombinant human interleukin-2. , 1985, Journal of biological response modifiers.

[23]  B. Giovanella,et al.  The nude mouse in cancer research. , 1985, Advances in cancer research.

[24]  A. Chang,et al.  Systemic administration of recombinant human interleukin-2 in mice. , 1984, Journal of biological response modifiers.

[25]  D. Nelson,et al.  Antigen-stimulated human B cell clones are committed to the production of a single class of antibody in vitro. , 1984, Journal of immunology.

[26]  E. Shevach,et al.  Identification and initial characterization of a rat monoclonal antibody reactive with the murine interleukin 2 receptor-ligand complex. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[27]  M. Gately,et al.  In vitro studies on the cell-mediated immune response to human brain tumors. I. Requirement for third-party stimulator lymphocytes in the induction of cell-mediated cytotoxic responses to allogeneic cultured gliomas. , 1982, Journal of the National Cancer Institute.

[28]  R. Suzuki,et al.  Studies of murine large granular lymphocytes. II. Tissue, strain, and age distributions of LGL and LAL. , 1982, Journal of immunology.

[29]  B. Murphy,et al.  In vitro production of anti-influenza virus antibody after intranasal inoculation with cold-adapted influenza virus. , 1981, Journal of immunology.

[30]  A. Munck,et al.  T cell growth factor receptors. Quantitation, specificity, and biological relevance , 1981, The Journal of experimental medicine.

[31]  N. Tamaoki,et al.  In vivo effects of anti-asialo GM1. I. Reduction of NK activity and enhancement of transplanted tumor growth in nude mice. , 1981, Journal of immunology.

[32]  J. Roder,et al.  The beige mutation in the mouse selectively impairs natural killer cell function , 1979, Nature.

[33]  Kendall A. Smith,et al.  T cell growth factor: parameters of production and a quantitative microassay for activity. , 1978, Journal of immunology.

[34]  H. RINDERKNECHT,et al.  Ultra-Rapid Fluorescent Labelling of Proteins , 1962, Nature.